Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List Lengea You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and